CBD: research and patient questions (Page 2)

Twenty healthy adults took a hemp-derived oil product that contains a substance called cannabidiol, either by mouth or rubbed onto the skin, at different times. Blood was drawn over the following day to see how much of the substance entered the body by each route.

This review pooled results from many earlier studies of a mouth spray containing two cannabis compounds, called nabiximols, in adults with multiple sclerosis. The researchers looked at whether it helped with problems other than the muscle stiffness it is already approved for, such as bladder, sleep, muscle spasms and walking.

Researchers pooled results from 43 earlier surveys covering almost 390,000 people, mostly in the United States and Europe. They looked at how many people had ever used, or recently used, a product made from the non-intoxicating part of cannabis, called cannabidiol (CBD), and compared North America with Europe.

This study looked at how safe it is for people who drink alcohol moderately to also use a substance called cannabidiol (CBD). The researchers tested this in two settings: a lab and in people's homes over a longer period.

This review looked at many earlier studies to see whether using CBD products or hemp oil can cause a person to fail a drug test for cannabis. Most of the studies involved adult volunteers or patient reports, and they tested blood, urine, saliva and hair samples.

This review gathered brain scan studies in adults that gave cannabidiol, a non-intoxicating part of the cannabis plant, and compared it with a dummy pill while people were stressed or anxious. The authors combined the results from twelve small studies.

While preclinical and early human studies suggest that oral and topical CBD may offer safe, adjunctive pain relief with minimal side effects, current clinical evidence remains inconclusive due to small sample sizes. Clinicians should counsel patients on the current paucity of robust data, potential significant costs, and the lack of product regulation when considering over-the-counter cannabinoid therapies.

This study involved patients diagnosed with Parkinson's disease who were given either a cannabidiol-enriched cannabis product or a placebo. The researchers aimed to see how effective the cannabis product was in improving symptoms of Parkinson's disease over an eight-week period. They measured various health outcomes to assess the impact of the treatment.

While adjunctive transdermal cannabidiol (ZYN002) at doses of 195 mg or 390 mg daily did not demonstrate statistically significant superiority over placebo in reducing focal seizure frequency over 12 weeks, it exhibited an excellent safety and tolerability profile with minimal gastrointestinal or hepatic adverse events. The favorable long-term tolerability and signals of seizure reduction in the open-label extension suggest that future clinical trials evaluating higher doses of transdermal cannabidiol in adult focal epilepsy are warranted.

Low-dose oral synthetic cannabidiol (20-30 mg daily) failed to provide clinically meaningful pain relief or improve sleep and mood scores compared to placebo in patients with hand osteoarthritis or psoriatic arthritis. Integrative clinicians should recognize that conservative low-dose CBD monotherapy is unlikely to suffice for moderate-to-severe arthritic pain, and higher dosages or full-spectrum formulations should be formally evaluated in future adequately powered trials.